Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2021 Dec 14;21(2):347–358. doi: 10.1158/1535-7163.MCT-21-0310

Figure 6. Treatment with 5-Fu depletes MDSCs and restores cytotoxic T cells in the BM of OB-Runx2−/− mice.

Figure 6.

Immunosuppressive cells and immune effector cells within the BM of OB-Runx2−/− and OB-Runx2+/+ mice were assessed by flow cytometry after 4-week treatment with PBS, BTZ, 5-Fu, or BTZ+5-Fu as depicted in Fig. 5 (n=5 mice/group). A, Percentage of MDSCs (Gr1+ CD11bhi) in the BM cell population. B-D, Relative expression of iNOS (B), arginase 1 (C), and IL-10 (D) in total MDSCs (Gr1+ CD11bhi). E, Gating strategy for identifying CD8+ T cells and CD8+ T cells expressing exhaustion and activation markers in the BM cell population. F, Percentage of CD8+ T cells among all CD3+ T cells (CD3+CD8+) in the BM. G-J, Percentage of CD8+ T cells in the BM expressing PD-1 (G), TIM-3 (H), granzyme B (I), or IFN-γ (J). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001. ns, not significant.